MGRX

Company Overview — What Does MANGOCEUTICALS, INC. Do?

We plan to connect consumers to licensed healthcare professionals through our recently launched website at www.MangoRX.com for the provision of care via telehealth on our customer portal and plan to also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. To date, we have developed what we believe is a go-to-market strategy inclusive of product development, operations, marketing and advertising; however, we have not produced a significant amount of products and have generated only nominal revenues to date. We have identified men’s wellness telemedicine services and products as a growing sector in recent years and especially related to the areas of erectile dysfunction (“ED”) products. We have developed and are currently in the process of preparing to commercially market a new brand of ED product under the brand name “Mango.” This product is produced at a compounding pharmacy and is available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. This product currently includes the following three ingredients: Tadalafil (the active ingredient in Cialis) and Oxytocin, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs; and L-Arginine, an amino acid that is available as a dietary supplement. However, the fact that Tadalafil and Oxytocin are used in FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean that these ingredients will prove safe when combined into a single formulation to treat ED. We currently offer two dosage levels of our Mango ED product and anticipate doctors prescribing a dosage based on the needs and medical history of the patient. Our Mango ED product currently includes the following amounts of the three ingredients discussed above: (1) Tadalafil (10 milligrams (mg)), Oxytocin (100 International units (IU)) and L-Arginine (50mg); and (2) Tadalafil (20mg), Oxytocin (100IU) and L-Arginine (50mg). Our Mango ED product has not been, and will not be, approved by the FDA and instead we plan to produce and sell our products, including our Mango ED product, under an exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act, as discussed below. We are not aware of any clinical studies involving the administration of tadalafil sublingually at the doses we provide patients, or the compounding of tadalafil, oxytocin, and L-arginine to treat ED, as is contemplated by our ED product. We are, however, aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of Tadalafil and Sildenafil (the active ingredient in Viagra). Additionally, because our Mango ED product is being specially compounded for the customer by a pharmacist with a physician’s prescription and because the ingredients for our Mango ED product will be publicly disclosed, this product formula can be replicated by other companies. Because our ED product has not been, and will not be, approved by the FDA, our product has not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death. If this were to occur, we could be subject to litigation and governmental action, which could result in costly litigation, significant fines, judgments or penalties. We currently anticipate using approximately $1.8 million of the net proceeds of this offering to finance the marketing and operational expenses associated with the planned marketing of our Mango ED product. We launched our website in mid-November 2022. To date, we have sold only a small amount of products and generated only nominal revenues. We plan to market and seek to sell commercial quantities of our Mango ED product in the first quarter of 2023 following this offering. Mango has been formulated as a Rapid Dissolve Tablet (“RDT”) using a sublingual (applied under the tongue) delivery system to bypass the stomach and liver. It is a generally established principle that sublingual drug absorption through the oral mucosa is generally faster than drug absorption through the gastrointestinal tract. This is because sublingual drugs that are absorbed through the oral mucosa directly enter the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver (see H. Zhang et al., Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications, 41 Clin Pharmacokinet 661, 662 (2002). Though the active ingredients that comprise our Mango product are meant to treat ED – an issue that according to a 2018 study published in The Journal of Sexual Medicine has been estimated to affect over one-third of today’s men’s population (with prevalence increasing with age) – we are also aiming to brand ourselves as a lifestyle company marketed to men seeking enhanced sexual vitality, performance, and overall mood and confidence. Mango is expected to be sold exclusively online via our recently launched website at www.MangoRX.com. Our principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248, and our telephone number is (214) 242-9619. Our principal website address is www.mangorx.com. The Company was formed as a Texas corporation on October 7, 2021. At the time of the formation of the Company, the Company was wholly-owned by American International. Jacob D. Cohen, our Chairman and Chief Executive Officer, holds majority voting control over American International and also serves as the Chief Executive Officer, President and a member of the Board of Directors of American International. American International formed the Company with the intent of focusing on developing, marketing and selling a variety of men’s wellness products and services via a telemedicine platform. On June 16, 2022, American International entered into and closed the transactions contemplated by a Stock Purchase Agreement (the “SPA”) with Cohen Enterprises, Inc. (“Cohen Enterprises”), which is owned by Mr. Cohen, the Chairman and Chief Executive Officer of the Company, and who is also the majority shareholder of the Company. American International determined to divest its interests in the Company in order to focus on developing its pharmacy business through its 51% ownership of Epiq Scripts, which entity the Company has entered into the Master Services Agreement. MANGOCEUTICALS, INC. (MGRX) is classified as a micro-cap stock in the Healthcare sector. The company is led by CEO Jacob D. Cohen. With a market capitalization of $6M, MGRX is one of the notable companies in the Healthcare sector.

MANGOCEUTICALS, INC. (MGRX) Stock Rating — Avoid (April 2026)

As of April 2026, MANGOCEUTICALS, INC. receives a Avoid rating with a composite score of 16.3/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.MGRX ranks #4,439 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, MANGOCEUTICALS, INC. ranks #841 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MGRX Stock Price and 52-Week Range

MANGOCEUTICALS, INC. (MGRX) currently trades at $0.34. The stock gained $0.00 (0.1%) in the most recent trading session. The 52-week high for MGRX is $5.20, which means the stock is currently trading -93.5% from its annual peak. The 52-week low is $0.33, putting the stock 2.8% above its annual trough. Recent trading volume was 472K shares, suggesting relatively thin trading activity.

Is MGRX Overvalued or Undervalued? — Valuation Analysis

MANGOCEUTICALS, INC. (MGRX) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.41x, versus the sector average of 2.75x. The price-to-sales ratio is 12.65x, compared to 1.66x for the average Healthcare stock.

At current multiples, MANGOCEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

MANGOCEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

MANGOCEUTICALS, INC. (MGRX) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -130.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -123.5% versus the sector average of -33.1%.

On a margin basis, MANGOCEUTICALS, INC. reports gross margins of 58.2%, compared to 71.5% for the sector. The operating margin is -4461.4% (sector: -66.1%). Net profit margin stands at -4548.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -48.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MGRX Debt, Balance Sheet, and Financial Health

MANGOCEUTICALS, INC. has a debt-to-equity ratio of 6.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.74x, suggesting adequate working capital coverage. Total debt on the balance sheet is $100,000. Cash and equivalents stand at $481,281.

MGRX has a beta of 1.35, meaning it is more volatile than the broader market — a $10,000 investment in MGRX would be expected to move 35.0% more than the S&P 500 on any given day. The stability factor score for MANGOCEUTICALS, INC. is 12/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

MANGOCEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, MANGOCEUTICALS, INC. reported revenue of $495,029 and earnings per share (EPS) of $-2.17. Net income for the quarter was $-20M. Gross margin was 58.2%. Operating income came in at $-19M.

In FY 2025, MANGOCEUTICALS, INC. reported revenue of $456,021 and earnings per share (EPS) of $-2.17. Net income for the quarter was $-21M. Gross margin was 54.9%. Revenue grew -26.0% year-over-year compared to FY 2024. Operating income came in at $-18M.

In Q3 2025, MANGOCEUTICALS, INC. reported revenue of $84,246 and earnings per share (EPS) of $-0.69. Net income for the quarter was $-8M. Gross margin was 60.4%. Revenue grew -36.8% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, MANGOCEUTICALS, INC. reported revenue of $168,109 and earnings per share (EPS) of $-0.57. Net income for the quarter was $-5M. Gross margin was 53.5%. Revenue grew 3.0% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, MANGOCEUTICALS, INC. has demonstrated a growth trajectory, with revenue expanding from $163,163 to $495,029. Investors analyzing MGRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MGRX Dividend Yield and Income Analysis

MANGOCEUTICALS, INC. (MGRX) does not currently pay a dividend. This is common among smaller companies in the Healthcare industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MGRX Momentum and Technical Analysis Profile

MANGOCEUTICALS, INC. (MGRX) has a momentum factor score of 7/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

MGRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, MANGOCEUTICALS, INC. (MGRX) ranks #841 out of 838 stocks based on the Blank Capital composite score. This places MGRX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MGRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MGRX vs S&P 500 (SPY) comparison to assess how MANGOCEUTICALS, INC. stacks up against the broader market across all factor dimensions.

MGRX Next Earnings Date

No upcoming earnings date has been announced for MANGOCEUTICALS, INC. (MGRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MGRX? — Investment Thesis Summary

The quantitative profile for MANGOCEUTICALS, INC. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Momentum is weak at 7/100, a headwind for near-term performance. High volatility (stability score 12/100) increases portfolio risk.

In summary, MANGOCEUTICALS, INC. (MGRX) earns a Avoid rating with a composite score of 16.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MGRX stock.

Related Resources for MGRX Investors

Explore more research and tools: MGRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MGRX head-to-head with peers: MGRX vs AZN, MGRX vs SLGL, MGRX vs VMD.